yf_tkr_UTHR · 2026-08-24
United Therapeutics Corporation (NASDAQ:UTHR) has moved ralinepag into formal FDA review after the regulator accepted its New Drug Application for the investigational pulmonary arterial hypertension treatment. The FDA filing acceptance establishes a Prescription Drug User Fee Act (PDUFA) target action date of June 24, 2027, giving investors a defined regulatory catalyst following positive Phase 3 results.
Read the original at yf_tkr_UTHR ↗
Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.
Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。